Jeena Sikho (JSLL) Q2 FY27 Results: Beds to Double, Margin Falls
Jeena Sikho Lifecare (NSE: JSLL) - Share price: ₹342.1 (13 November 2026, as printed in the company's own presentation) - Market cap: ₹4,253.13 crore (same date and source) - P/E: about 20 times, my own sum from the presentation: ₹4,253 crore divided by profit of ₹214 crore over the last 12 months (FY26 profit ₹222 crore, minus H1 FY26 ₹110 crore, plus H1 FY27 ₹102 crore) - 52-week high / low: ₹809.0 / ₹315.4, so the price is about 58% below its high and about 8% above its low - ROCE: 46% (3-year average, as stated by the company)
Jeena Sikho Lifecare (JSLL) Q2 FY27 results: beds to double from 2,424 to 5,000, but the September-quarter operating margin fell to 31%.
It says each bed costs only ₹3-4 lakh to build and pays back fast. The catch is in the latest numbers: in the September 2026 quarter sales rose 24%, but the operating margin fell to 31% and profit fell 38%. The growth is visible. The profit growth is not, at least for now.
All figures below come from the company's Q2 FY27 investor presentation dated 15 November 2026, unless stated otherwise.
What Jeena Sikho Lifecare (JSLL) does
Jeena Sikho Lifecare is an Ayurveda healthcare company with two businesses. It was incorporated in 2017. Its first Ayurveda health care centre opened in Chandigarh in 2013, and it sold its first products in 2009. It listed on the NSE in April 2022 and moved to the NSE and BSE main boards in August 2025.
- Services (43% of H1 FY27 sales, ₹197 crore): 62 hospitals and 60 clinics and day care centres in 23 states and 100+ cities. Gross margin 90%. - Products (57%, ₹262 crore): 440+ Ayurveda medicines and wellness products, sold through its own centres, by phone and online, and to 33 franchise centres. Gross margin 87%.
The two feed each other. A patient who visits a clinic buys medicines afterwards. The company calls this a cross-sell flywheel. It has 52 NABH-accredited units, with 12 more in process, and 608 certified Ayurveda doctors.
Jeena Sikho Lifecare growth that is already there
₹ crore FY22 FY23 FY24 FY25 FY26 ------------------ Sales 146.5 203.9 324.4 469.1 801.4 EBITDA 18.1 46.1 93.0 140.6 349.6 EBITDA margin 12% 23% 29% 30% 44% Net profit 11.3 33.7 69.2 79.9 222.2
The company says sales grew at 53% a year over FY22-FY26 and profit at 111% a year. Gross margin stayed at 88-90% throughout. So the jump in profit came from spreading costs over a bigger business, not from higher prices.
The growth came from more patients, not from charging more:
- Inpatient (IPD) patients: 13,159 in FY24, 24,578 in FY25, 40,454 in FY26. - In H1 FY27, IPD volumes rose 23% to 22,480, outpatient (OPD) volumes rose 17% to 3.1 lakh, day care volumes rose 27% to 40,619, and virtual consultations rose 39% to 1.36 lakh.
Jeena Sikho Lifecare growth plan: 5,000 beds
Management's plan, in its own words, is to scale towards 5,000 beds in two to five years and 10,000 in five to ten years. It also plans to go from 122 hospitals and clinics today to 142 in two to five years and 172 in five to ten years.
- 2,424 beds are operating. 460 more are in the pipeline, so the total with pipeline is 3,031. - 573 beds were added in FY25 and 561 in FY26. - Upcoming facilities named in the presentation: Lucknow (160 beds), Bareilly (40), Ahmedabad (200) and Kalyani in West Bengal (60). The company says 4 facilities are in the pipeline. - A first wellness resort in Manali is signed: 108 rooms, 22 villas planned, 20+ acres of private forest, one helipad planned. No cost or opening date is given.
Why Jeena Sikho Lifecare says a new bed pays back
The presentation gives the unit economics of a 100-bed facility. These are management's own estimates, not audited results.
Item Company figure ------ Build cost for 100 beds ₹250-350 lakh (₹3-4 lakh per bed) Monthly running cost ₹1.35-1.4 crore Revenue per bed per day about ₹7,500 (including medicines) Monthly revenue at full occupancy about ₹300 lakh Break-even occupancy about 35% Time to reach 70% occupancy 12-18 months Payback, smaller hospitals under 6 months
By my arithmetic, 2,576 new beds (5,000 minus 2,424) at ₹3-4 lakh a bed is about ₹77-103 crore of equipment and fit-out. Compare that with FY26 cash from operations of ₹262 crore. The company funds growth from its own cash and has borrowings of only ₹0.4 crore against equity of ₹467 crore.
Where the Jeena Sikho Lifecare Q2 FY27 margin went
₹ crore Q2 FY27 Q2 FY26 Change H1 FY27 H1 FY26 Change --------------------- Sales 235.1 189.9 +24% 459.5 364.1 +26% EBITDA 72.0 92.1 -22% 164.1 170.9 -4% EBITDA margin 31% 48% -1,786 bps 36% 47% -1,120 bps Net profit 36.3 58.8 -38% 102.0 110.1 -7% EPS (₹) 2.92 4.73 -38% 8.21 8.86 -7%
Gross margin held at 88%, so the squeeze is in running costs. Management names three causes for H1 FY27:
- Advertising and promotion up ₹13.4 crore, on brand-building aimed at younger buyers (Gen Z), including television campaigns. - Employee costs up ₹4.1 crore, for extra staff hired ahead of planned expansion, plus pay revisions linked to performance. - Provision for expected credit losses up ₹2.5 crore, because of slower payments and settlements from government customers.
Depreciation also rose 58% to ₹31.8 crore in H1 because the network is larger. Other income was a negative ₹2.3 crore in Q2 (₹11.7 crore in H1).
The managing director calls these investments in brand and capability. He expects operating leverage, meaning costs growing slower than sales, to return as the new facilities mature. That is the company's expectation, not a result.
Jeena Sikho Lifecare cash, receivables and balance sheet
₹ crore FY22 FY23 FY24 FY25 FY26 ------------------ Cash from operations 17.5 17.2 36.7 84.5 262.0 Cash used in investing 19.6 57.2 18.0 64.5 211.1 Trade receivables 9.0 22.1 41.2 85.0 69.9 Fixed assets (PP&E) 28.2 59.7 66.8 92.3 117.0
- FY26 cash from operations (₹262 crore) was higher than FY26 profit (₹222 crore). Profit is turning into cash. - Free cash flow was ₹51 crore in FY26 after ₹211 crore of investing. The company counts cash from operations less cash used in investing. - Receivables (money customers still owe) fell from ₹85 crore to ₹70 crore even as sales rose. The company puts this at 32 days of sales in FY26 against 66 days in FY25. The presentation says it computed these days itself. - The company says return on equity was 61% in FY26, on average equity. Borrowings were ₹0.4 crore. - Government customers are a watch point: the Q2 provision rose because collections from them are slower. The company says it is empanelled with CGHS, CAPF, ECHS and several state government schemes.
Jeena Sikho Lifecare occupancy and revenue per bed: the weak spot
New beds are not filling as fast as they are built.
- Occupancy was 55% in Q2 FY27, against 59% in Q1 FY27 and 57% in Q2 FY26. For H1 FY27 it was 57%, the same as last year. - Revenue per occupied bed per day (ARPOB) was ₹7,500 in Q2 FY27, against ₹8,360 in Q1 and ₹8,324 a year ago. For H1 it was ₹7,917, down 5% from ₹8,306. - The company's break-even occupancy is about 35%, and it targets about 70% for a mature facility.
Beds rose only 10% year on year (2,200 to 2,412), while inpatient volumes rose 23%. Management says it wants to improve use of recently added capacity.
Who owns Jeena Sikho Lifecare shares
- Promoters: 63.67% - Public: 31.30% - FII and DII together: 5.03%
All three are as on 30 September 2026. The presentation does not show earlier quarters, so no trend is given here. This article does not name individual fund holders.
What Jeena Sikho Lifecare management says it will do
These are the company's own forward-looking statements, not facts and not promises. The company gives no revenue or profit target.
- Scale to 5,000 beds in two to five years, and 10,000 in five to ten years. - Go from 122 hospitals and clinics to 142 in two to five years, and 172 in five to ten years. - Open the 460 beds in the pipeline, and the four named upcoming facilities. - Improve use of recently added beds. - Widen the product range: the Dr. DS range, protein and joint-care products, pharmacy and retail roll-out, its own e-commerce platform and refill subscriptions. - Get NABH accreditation for the 12 units in process. - Enter premium wellness with the Manali resort. - Run a follow-on study with patients after a study on healthy people looked at how Ayurveda may lower disease risk. The company says it has published 200+ research papers. - Fund all of it from internal cash.
How the Jeena Sikho Lifecare valuation compares
This article does not include a comparison with listed peers. At about 20 times last-12-months profit, the price reflects a sharp fall from the ₹809 high. The lower price may reflect the fall in margin.
Jeena Sikho Lifecare risks to watch
- Margin could keep falling. EBITDA margin went from 47% in H1 FY26 to 36% in H1 FY27, and was 31% in Q2. If new facilities fill slowly, operating leverage may not return. - Empty new beds. Occupancy is flat at 57% and ARPOB is down 5% while capacity grows. - Government payments. Higher provisions point to slower collections from government customers. - Rising fixed costs. Depreciation is up 58%, and doubling the beds will add more. - Advertising may not pay back. The ₹13.4 crore rise in promotion spend needs to turn into patients. - Founder-led brand. The deck centres on the managing director and his methods. This is a business concentration the reader should weigh. - Evidence for treatment claims. The deck cites Nobel Prize research and patient testimonials to support its approach. Those are not clinical trial results for the company's own treatments. A reader should treat the company's own research papers and testimonials as claims, not proof.
The key point Beds, patients and sales are all growing fast, and the plan to double beds costs little per bed. But the profit fell 38% over the year to September, and 45% from the June quarter. The question is not whether the company can add beds. It is whether the new beds will fill.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://nsearchives.nseindia.in/corporate/JEENASIKHO15112026211302IntimationInvestorPPT-Sign.pdf